Thelin sitaxsentan regulatory update

FDA intends to accept for filing an NDA for Thelin sitaxsentan to treat pulmonary arterial hypertension (PAH) on July 23. The PDUFA date is March 24, 2006. FDA requested a plan for the study of Thelin...